Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of TA 8995 alone and with statins in mild dyslipidaemia
NL-OMON40324Phase 2Active, not recruiting
- Sponsor
- Xention Ltd.
- Start
- Sep 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obicetrapib in lipid disorder (9 arms), sponsored by Xention Ltd. Primary endpoints: Change in HDL cholesterol and Change in LDL cholesterol. Started Sep 2013; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
lipid disorder
Beyond the preview
Go deeper on NL-OMON40324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40324.